Luca Bertero

ORCID: 0000-0001-9887-7668
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Glioma Diagnosis and Treatment
  • Brain Metastases and Treatment
  • Cancer Immunotherapy and Biomarkers
  • Meningioma and schwannoma management
  • Radiomics and Machine Learning in Medical Imaging
  • Neuroblastoma Research and Treatments
  • Cancer, Hypoxia, and Metabolism
  • Lung Cancer Research Studies
  • Ovarian cancer diagnosis and treatment
  • Pituitary Gland Disorders and Treatments
  • Endometrial and Cervical Cancer Treatments
  • Neurofibromatosis and Schwannoma Cases
  • Neuroendocrine Tumor Research Advances
  • Sarcoma Diagnosis and Treatment
  • Nanoplatforms for cancer theranostics
  • RNA modifications and cancer
  • Uterine Myomas and Treatments
  • Cancer Genomics and Diagnostics
  • Ferroptosis and cancer prognosis
  • Colorectal and Anal Carcinomas
  • Cancer Treatment and Pharmacology
  • Lung Cancer Treatments and Mutations
  • Vascular Malformations Diagnosis and Treatment
  • AI in cancer detection
  • CAR-T cell therapy research

University of Turin
2016-2025

University of Milan
2024

Azienda Ospedaliera Citta' della Salute e della Scienza di Torino
2013-2023

Piedmont Reference Center for Epidemiology and Cancer Prevention
2013-2021

Heidelberg University
2018-2021

University Hospital Heidelberg
2018-2021

Vrije Universiteit Amsterdam
2020

University of Copenhagen
2020

Ospedale Sant'Anna
2020

Orlando Health
2013

Abstract In the 5th edition of WHO CNS tumor classification (CNS5, 2021), multiple molecular characteristics became essential diagnostic criteria for many additional types. For those tumors, an integrated, “histomolecular” diagnosis is required. A variety approaches exists determining status underlying markers. The present guideline focuses on methods that can be used assessment currently most informative and prognostic markers gliomas, glioneuronal neuronal tumors. main are systematically...

10.1093/neuonc/noad100 article EN cc-by-nc Neuro-Oncology 2023-06-02

Abstract Whole-brain radiotherapy (WBRT) is the treatment backbone for many patients with brain metastasis; however, its efficacy in preventing disease progression and associated toxicity have questioned clinical impact of this approach emphasized need alternative treatments. Given limited therapeutic options available these poor understanding molecular mechanisms underlying resistance metastatic lesions to WBRT, we sought uncover actionable targets biomarkers that could help refine patient...

10.1038/s41591-022-01749-8 article EN cc-by Nature Medicine 2022-04-01

Abstract This study aimed to analyze the human papillomavirus (HPV) genotype distribution in a large cohort of high‐grade vaginal intraepithelial neoplasia (VaIN) (vaginal HSIL, VaIN2/3) patients from two Italian referral centers. We included all with histologically confirmed VaIN2/3 Department Surgical Sciences, Sant'Anna Hospital, University Torino, Italy, and Ospedale Maggiore della Carità, Novara, between 2003 2022. After histological evaluation formalin‐fixed paraffin‐embedded samples,...

10.1002/jmv.29474 article EN cc-by-nc-nd Journal of Medical Virology 2024-02-01

Little information is available regarding the effect of conventional radiotherapy on glioma-related seizures. In this retrospective study, we analyzed seizure response and outcome following in a cohort 43 patients with glioma (33 grade II, 10 III) medically intractable epilepsy. At 3 months after radiotherapy, reduction was significant (≥50% frequency compared baseline) 31/43 (72%) whole series 25/33 (76%) II gliomas, whereas at 12 26/34 19/25 patients, respectively. Seizure observed more...

10.1093/neuonc/not109 article EN Neuro-Oncology 2013-07-28

Abstract The optimal combination of bevacizumab with cytotoxic or cytostatic drugs in recurrent glioblastoma is unknown. We performed a phase 2 trial combined and fotemustine for patients at first relapse after radiotherapy temozolomide. primary endpoint was 6-month progression-free survival (PFS), while secondary endpoints were overall (OS), response rate based on RANO criteria toxicity. Fifty-four GBM enrolled. authors observed PFS 42.6 % (95 CI 29.3–55.2) median 5.2 months 3.8–6.6). OS...

10.1007/s11060-013-1317-x article EN cc-by Journal of Neuro-Oncology 2013-11-30

Abstract Infection by SARS-CoV-2 has been shown to involve a wide range of organs and tissues, leading kaleidoscope clinical conditions. Within this spectrum, an involvement the fetal-maternal unit could be expected, but, so far, histopathological evaluation placentas delivered women with infection did not show distinct hallmarks. A consecutive series 11 placentas, 10 COVID-19 admitted our Obstetrics Gynecology clinic have investigated compared control cohort 58 pre-COVID-19 28 who had...

10.1007/s00428-021-03097-3 article EN cc-by Virchows Archiv 2021-05-01

Introduction Over the past two years, scientific community has witnessed an exponential growth in research focused on identifying prognostic biomarkers for melanoma, both pre-clinical and clinical settings. This surge studies reflects need of developing effective indicators field melanoma.

10.1080/14737159.2024.2314574 article EN Expert Review of Molecular Diagnostics 2024-02-01

Differentiated vulvar intraepithelial neoplasia (dVIN) is a high-risk preinvasive lesion and precursor of human papillomavirus-independent squamous cell carcinoma (VSCC). Due to its rarity, literature data on malignant potential are scant. The aim the study assess risk developing VSCC in patients surgically treated for dVIN not associated with (solitary dVIN) recurrence (dVIN-VSCC) at first diagnosis.

10.1111/aogs.14814 article EN cc-by-nc-nd Acta Obstetricia Et Gynecologica Scandinavica 2024-02-21

Abstract Meningiomas are the most common primary intracranial tumors of adults. For meningiomas that progress or recur despite surgical resection and radiotherapy, additional treatment options limited due to a lack proven efficacy. show recurring molecular aberrations, which may serve as predictive markers for systemic pharmacotherapies with targeted drugs immunotherapy, radioligand therapy. Here, we review evidence role wide range alterations including NF2, AKT1, SMO, SMARCE1, PIK3CA,...

10.1093/neuonc/noae253 article EN cc-by-nc Neuro-Oncology 2024-11-23

The significance of androgen receptor (AR) in breast cancer (BC) management is not fully defined, and it still ambiguous how the level AR expression influences oestrogen receptor-positive (ER+) tumours. aim present study was to analyse prognostic impact AR/ER ratio, evaluated by immunohistochemistry (IHC), correlating this value with clinical, pathological molecular characteristics. We retrospectively selected a cohort 402 ER+BC patients. On each tumour, IHC analyses for AR, ER, PgR, HER2...

10.1530/erc-17-0417 article EN Endocrine Related Cancer 2018-02-01
Coming Soon ...